Disposition and protein binding of valproic acid in the developing rat. 1994

L J Haberer, and G M Pollack
Division of Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360.

The disposition of valproic acid (VPA) in serum and brain tissue was examined in developing rats (5, 10, 20, and 60 days postpartum) following both single and multiple intraperitoneal doses of VPA. The binding of VPA to proteins in serum was determined ex vivo by ultrafiltration for each age group in pooled serum at various time points following VPA administration, as well as after in vitro addition of VPA (8-2400 micrograms/ml) to pooled rat serum from naive animals of each age. Concentration-time data for VPA in serum and brain tissue were fit simultaneously, assuming first-order absorption from the peritoneal injection site and first-order transfer of drug between serum and brain tissue. Kinetic analysis revealed that total clearance increased with postnatal age, whereas the volume of distribution and brain-to-serum partitioning of VPA decreased during development. Furthermore, enterohepatic recirculation, a well-described facet of VPA disposition in adult rats, was not evident from examination of the serum concentration-time profile in animals prior to the time of weaning. A progressive increase in the binding of VPA to proteins in serum was observed during postnatal development. The bound fraction determined ex vivo was less than that determined in vitro for all age groups, suggesting the possibility of competition for VPA binding sites by metabolite(s) formed in vivo.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

L J Haberer, and G M Pollack
January 1989, Therapeutic drug monitoring,
L J Haberer, and G M Pollack
October 1977, European journal of clinical pharmacology,
L J Haberer, and G M Pollack
July 2000, Drug metabolism and disposition: the biological fate of chemicals,
L J Haberer, and G M Pollack
July 1986, Chemical & pharmaceutical bulletin,
L J Haberer, and G M Pollack
May 1980, Neurology,
L J Haberer, and G M Pollack
November 1994, Clinical pharmacology and therapeutics,
L J Haberer, and G M Pollack
July 2006, Basic & clinical pharmacology & toxicology,
L J Haberer, and G M Pollack
May 1990, Pharmaceutical research,
Copied contents to your clipboard!